L-Annamycin for Injection in Combination With Cytarabine Injection as Second Line Therapy for Remission Induction in Adult Subjects With Refractory/Relapsed AML

Clinical trial NCT06788756 · RECRUITING

Trial details

NCT number: NCT06788756
Sponsor: Moleculin Biotech, Inc.
Status: RECRUITING
Phase: Phase 2, Phase 3
Study type: INTERVENTIONAL

Acute Myeloid Leukaemia (AML)

Start date: 2025-03-12
Primary completion: 2029-08-01
Enrollment: 312

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.